Weijian Pharmaceuticals and China Rare Disease Alliance strategically cooperate to help the construction of a healthy ecology for rare diseases

Boao, Hainan, October 8, 2021/PRNewswire/ - September 30, 2021 (Hainan·Boao), Hong Kong Weijian Pharmaceutical Group ("Vaijian Pharmaceutical") and China Rare Disease Alliance formally signed a five-year strategic cooperation Agreement

Left: Li Linkang, Executive Director of China Rare Diseases Alliance.

On the same day, as the first project of the strategic cooperation between the two parties, "Guidelines for Diagnosis, Treatment and Management of Urea Cycle Disorders in China in 2022", the kick-off meeting was held in Boao.

Significance of the signing of the contract between Weijian Pharmaceutical and China Rare Disease Alliance

This strategic cooperation is to integrate China's rare disease prevention and control resources, mobilize medical institutions, scientific research institutes, social organizations, and pharmaceutical companies to jointly promote the diagnosis and treatment of rare diseases, improve the level of rare disease treatment, and ultimately benefit patients

Weijian Pharmaceutical is an innovative biopharmaceutical company based in China and facing the world.

How to build a healthy ecosystem for rare diseases

Weijian Pharmaceutical will use its unique two-wheel drive business model to help the global availability of innovative drugs for rare disease drugs

Ravicti® (glyceryl phenylbutyrate) is a product suitable for urea cycle disorders

The Boao Lecheng Weijian Rare Disease Clinical Medical Center, jointly established by Weijian Medicine, Lecheng Administration and Future Hospital, has introduced 32 innovative drugs that have been marketed overseas but have not been approved in China and have been used successively.

As a member of the China Rare Disease Alliance, Weijian Pharmaceutical will actively implement the purpose of the China Rare Disease Alliance, promote major breakthroughs in the research of rare diseases in medicine, improve the prevention and protection of rare diseases, and promote the clinical, scientific research and orphan drugs for rare diseases.

The first landing project of the strategic cooperation between Weijian Pharmaceutical and China Rare Disease Alliance

The first project of the strategic cooperation is the formulation and promotion of the "Guidelines for the Diagnosis, Treatment and Management of Urea Cycle Disorders in China in 2022"

"Guidelines for the Diagnosis, Treatment and Management of Urea Cycle Disorders in China in 2022" was initiated by the China Rare Diseases Alliance, led by Professor Gu Xuefan from Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

Guide kick-off meeting

This is the first project initiated by the strategic cooperation between Weijian Pharmaceutical, Boao Lecheng Weijian Rare Disease Clinical Medicine Center and China Rare Disease Alliance

About Weijian Pharmaceutical

Hong Kong Weijian Pharmaceutical Group was established in 2006.

About Boao Lecheng Weijian Rare Disease Clinical Medicine Center

Boao Lecheng Weijian Rare Disease Clinical Medicine Center (hereinafter referred to as the "center") was established in April 2020.

About China Rare Disease Alliance

The China Rare Disease Alliance is approved by the Medical Administration of the National Health Commission and led by Peking Union Medical College Hospital, China Medical Innovation Promotion Association, China Hospital Association, and China Research Hospital Association.

Source: Weijian Pharmaceutical